Fact Check: Regeneron Pharmaceuticals previously announced it would purchase most of 23andMe’s assets for $256 million after winning a bankruptcy auction.

Fact Check: Regeneron Pharmaceuticals to Purchase 23andMe for $256 Million

What We Know

Regeneron Pharmaceuticals has announced its intention to acquire 23andMe for $256 million following a bankruptcy auction. This acquisition comes after 23andMe filed for Chapter 11 bankruptcy protection in March 2025, during which it sought to sell "substantially all of its assets" as part of a court-approved reorganization plan (AP News, New York Times). The deal includes 23andMe's Personal Genome Service and Total Health and Research Services but excludes its Lemonaid Health subsidiary, which is set to be wound down (AP News, CNBC).

The acquisition is still pending approval from the U.S. Bankruptcy Court for the Eastern District of Missouri and regulatory bodies, with expectations for the deal to close in the third quarter of 2025 (New York Times, GlobeNewswire). Regeneron has committed to upholding 23andMe’s privacy policies and ensuring that customer data is handled in accordance with existing consents and legal requirements (AP News, Regeneron Press Release).

Analysis

The claim that Regeneron Pharmaceuticals will purchase most of 23andMe’s assets for $256 million is supported by multiple reputable sources. The announcement from Regeneron itself confirms the acquisition and details the financial terms, which adds credibility to the claim (Regeneron Press Release). Furthermore, major news outlets like the New York Times and AP News have reported on this transaction, providing additional context about the circumstances leading to the bankruptcy and the implications for customer data privacy (New York Times, AP News).

However, it is essential to note that while the deal has been announced, it is still subject to court approval and regulatory scrutiny. This introduces a level of uncertainty, as the finalization of the acquisition depends on these external factors (CNBC, GlobeNewswire). The reliability of the sources reporting this information is high, as they include established news organizations and official press releases from Regeneron.

Conclusion

The claim that Regeneron Pharmaceuticals previously announced it would purchase most of 23andMe’s assets for $256 million after winning a bankruptcy auction is True. The information is corroborated by multiple credible sources, including direct statements from Regeneron and coverage by major news outlets. While the deal is pending approval, the essential details of the acquisition have been clearly established.

Sources

1. Biotechnology company Regeneron buying 23andMe for $256 million
2. 23andMe to Be Bought by Biotech Company for $256 Million
3. Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for ...
4. Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
5. Regeneron, A Leading U.S. Biotechnology Company, to Acquire
6. Regeneron to buy 23andMe out of bankruptcy for $256 million
7. Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for ...
8. Anne Wojcicki to buy back 23andMe and its data for $305 million